Global Strategic Fund Ii L.... Net Worth

The estimated Net Worth of Global Strategic Fund Ii L.... is at least $358 Thousand dollars as of 25 January 2018. Global L owns over 265,000 units of Menlo Therapeutics stock worth over $357,750 and over the last 7 years Global sold MNLO stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Global L MNLO stock SEC Form 4 insiders trading

Global has made over 1 trades of the Menlo Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently Global bought 265,000 units of MNLO stock worth $4,505,000 on 25 January 2018.

The largest trade Global's ever made was buying 265,000 units of Menlo Therapeutics stock on 25 January 2018 worth over $4,505,000. On average, Global trades about 265,000 units every 0 days since 2018. As of 25 January 2018 Global still owns at least 265,000 units of Menlo Therapeutics stock.

You can see the complete history of Global L stock trades at the bottom of the page.

What's Global L's mailing address?

Global's mailing address filed with the SEC is 1700 Owens St #595, San Francisco, CA 94158, USA.

Insiders trading at Menlo Therapeutics

Over the last 7 years, insiders at Menlo Therapeutics have traded over $3,825,000 worth of Menlo Therapeutics stock and bought 3,655,938 units worth $21,205,011 . The most active insiders traders include Advisors Llcperceptive Life..., Llc Fmr, and Albert Cha. On average, Menlo Therapeutics executives and independent directors trade stock every 85 days with the average trade being worth of $572,944. The most recent stock trade was executed by Sharon Barbari on 20 August 2020, trading 75,000 units of MNLO stock currently worth $111,000.

What does Menlo Therapeutics do?

Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Redwood City, CA.

Complete history of Global L stock trades at Menlo Therapeutics

Menlo Therapeutics executives and stock owners

Menlo Therapeutics executives and other stock owners filed with the SEC include:

• Elisabeth Sandoval,
  Independent Director
• Patrick LePore,
  Independent Director
• Anthony Bruno,
  Director
• Rex Bright,
  Director
• Sharon Barbari,
  Director
• Matthew Wiley,
  Chief Commercial Officer
• Mutya Harsch,
  Chief Legal Officer, General Counsel
• Ronald Krasnow,
  Chief Compliance Officer
• Iain Stuart,
  Chief Scientific Officer
• Andrew Saik,
  Chief Financial Officer, Treasurer
• David Domzalski,
  Chief Executive Officer, Director
• Steven L Basta,
  Director
• Advisors Llcperceptive Life...,
  
• Ilan Hadar,
  CFO and Country Manager
• Stanley Hirsch,
  Director
• Partners 2007 Gp, L.P.Presi...,
  
• Global Strategic Fund Ii L....,
  10% owner
• Ventures Llc Remeditex,
  10% owner
• Capital Viii, Llc Vivo Capi...,
  
• Albert Cha,
  Director
• Llc Fmr,
  
• Scott M Whitcup,
  Director
• Mary Spellman,
  Chief Medical Officer
• Kristine M Ball,
  See Remarks
• David W J Mcgirr,
  Director
• Paul L Berns,
  Director
• Ted Ebel,
  Director
• Aaron Royston,
  Director
• Paul Kwon,
  Chief Scientific Officer